{
    "2021-12-12": [
        [
            {
                "time": "",
                "original_text": "医药投向标|腾盛博药新冠中和抗体获批 西安新通科创板IPO获受理 鞍石生物完成超2亿美元A轮融资",
                "features": {
                    "keywords": [
                        "腾盛博药",
                        "新冠中和抗体",
                        "西安新通",
                        "科创板IPO",
                        "鞍石生物",
                        "A轮融资"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}